1. Olesińska, M, Saletra, A. Quality of life in systemic lupus erythematosus and its measurement. Reumatologia 2018; 56(1): 45–54.
Google Scholar | Crossref | Medline2. Keeling, SO, Vandermeer, B, Medina, J, et al. Measuring disease activity and damage with validated metrics: a systematic review on mortality and damage in systemic lupus erythematosus. J Rheumatol 2018; 45(10): 1448–1461.
Google Scholar | Crossref | Medline3. Arora, S, Nika, A, Trupin, L, et al. Does systemic lupus erythematosus care provided in a lupus clinic result in higher quality of care than that provided in a general rheumatology clinic? Arthritis Care Res 2018; 70(12): 1771–1777.
Google Scholar | Crossref4. Santos-Moreno, P, Castillo, P, Villarreal, L, et al. clinical outcomes of patients with rheumatoid arthritis treated in a disease management program: real-world results. Open Access Rheumatol Res Rev 2020; Volume 12: 249–256.
Google Scholar5. Agency For Clinical Innovation . Understanding the Process to Develop a Model of Care an ACI Framework. Chatswood NSW: Agency For Clinical Innovation, 2013.
Google Scholar6. Hochberg, MC . Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40(9): 1725.
Google Scholar | Crossref | Medline7. van Vollenhoven, R, Bertsias, G, Doria, A, et al. OP0296 The 2021 DORIS definition of remission in SLE–Final recommendations from an international task force. Ann Rheum Dis 2021; 80: 181–182.
Google Scholar | Crossref8. Franklyn, K, Lau, CS, Navarra, SV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 2016; 75(9): 1615–1621.
Google Scholar | Crossref | Medline9. Mosca, M, Tani, C, Aringer, M, et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011; 10(7): 383–388.
Google Scholar | Crossref | Medline10. Fanouriakis, A, Kostopoulou, M, Alunno, A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 20192019; 78(6): 736–745.
Google Scholar | Crossref | Medline11. Kernder, A, Richter, JG, Fischer-Betz, R, et al. Quality of care predicts outcome in systemic lupus erythematosus: a cross-sectional analysis of a German long-term study (LuLa cohort). Lupus 2020; 29(2): 136–143.
Google Scholar | SAGE Journals | ISI12. Ugarte-Gil, MF, Wojdyla, D, Pons-Estel, GJ, et al. Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin american lupus cohort (GLADEL). Ann Rheum Dis 2017; 76(12): 2071–2074.
Google Scholar | Crossref | Medline13. Mok, CC, Ho, LY, Tse, SM, et al.. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus Ann Rheum Dis 2017; 76(8): 1420–1425.
Google Scholar | Crossref | Medline14. Ugarte-Gil, MF, Mendoza-Pinto, C, Reátegui-Sokolova, C, et al. Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. Lupus Sci Med 2021; 8: e000542.
Google Scholar | Crossref | Medline15. Etchegaray-Morales, I, Méndez-Martínez, S, Jiménez-Hernández, C, et al. Factors associated with health-related quality of life in Mexican lupus patients using the LupusQoL. PLoS One 2017; 12(1): e0170209–10.
Google Scholar | Crossref | Medline